Kidney DiseaseNCT07597005
Red Propolis Supplementation as a Strategy in Chronic Kidney Disease
A study testing Red Propolis in people with Kidney Disease and Oxidative Stress, run by Universidade Federal Fluminense at 1 site in Brazil.
Trial summary
The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Kidney Disease, Oxidative Stress, Chronic Kidney Disease
- What is being tested?
- Red Propolis
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteBrazil
- Study dates
- 30 Sep 2025to 31 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients with CKD stages 3-5 under conservative management
Who cannot join
- pregnant,
- lactating,
- smoker
- patients using antibiotics and antioxidant supplements in the last three months
- patients with autoimmune and infectious diseases,
- patients with cancer, liver disease, and AIDS
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Brazil1 site, 1 recruiting
- Recruiting
Denise Mafra
Rio de Janeiro, Rio de Janeiro, 22260050
About this study
Official title: Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease
The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.
Read the detailed description
Chronic kidney disease (CKD) is associated with chronic systemic inflammation and oxidative stress, which contribute to disease progression and adverse outcomes. Red propolis is a natural substance rich in bioactive compounds with potential anti-inflammatory and antioxidant effects. Clinical evidence on its use in CKD patients is limited, and no studies have evaluated its impact on gene expression related to inflammation and oxidative stress. This randomized, double-blind, placebo-controlled trial will assess the effects of alcoholic extract of red propolis (200 mg/day for 8 weeks) on inflammatory and oxidative stress markers in patients with CKD stages 3-5 under conservative management. Blood samples will be collected at baseline and after intervention to evaluate routine biochemical parameters, inflammatory and oxidative stress markers, and gene expression. Nutritional status and dietary intake will also be assessed.
- Conditions
- Kidney Disease, Oxidative Stress, Chronic Kidney Disease, Inflammation
- Being tested
- Red Propolis, Placebo Control
- Keywords
- oxidative stress, red propolis, inflammation, chronic kidney disease
- Medical subject headings
- Kidney Diseases, Renal Insufficiency, Chronic, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Red PropolisDietary supplement
Participants will receive 200mg of red propolis capsules per day for two months.
Placebo ControlOther
Participants will receive 200mg of placebo capsules per day for two months.
| Study group | Role | What they receive |
|---|---|---|
| Red Propolis Group | Experimental | Patients with chronic kidney disease will receive capsules containing 200mg of red propolis / day for two months. Receives: Dietary Supplement: Red Propolis |
| Placebo Group | Placebo comparator | Patients with chronic kidney disease will receive capsules containing 200mg of placebo/ day for two months. Receives: Other: Placebo Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in inflammatory biomarkers
Changes in the IL-6 and TNF-α
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2026
- Study start30 Sep 2025
- Primary completion30 Nov 2025
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidade Federal Fluminense
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07597005
- Sponsor's protocol ID
- DeniseMafra23
- Status last verified
- May 2026
- First submitted
- 12 May 2026
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease
- ClinicalTrials.gov ID
- NCT07597005
- Acronym / sponsor ID
- DeniseMafra23
- Conditions
- Kidney Disease, Oxidative Stress, Chronic Kidney Disease, Inflammation
- Keywords
- oxidative stress, red propolis, inflammation, chronic kidney disease
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Universidade Federal FluminenseUniversity, hospital or other
- Study start
- 30 Sep 2025 (actual)
- Primary completion
- 30 Nov 2025 (actual)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 19 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.
Detailed description
Chronic kidney disease (CKD) is associated with chronic systemic inflammation and oxidative stress, which contribute to disease progression and adverse outcomes. Red propolis is a natural substance rich in bioactive compounds with potential anti-inflammatory and antioxidant effects. Clinical evidence on its use in CKD patients is limited, and no studies have evaluated its impact on gene expression related to inflammation and oxidative stress. This randomized, double-blind, placebo-controlled trial will assess the effects of alcoholic extract of red propolis (200 mg/day for 8 weeks) on inflammatory and oxidative stress markers in patients with CKD stages 3-5 under conservative management. Blood samples will be collected at baseline and after intervention to evaluate routine biochemical parameters, inflammatory and oxidative stress markers, and gene expression. Nutritional status and dietary intake will also be assessed.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Red Propolis Group | Experimental | Dietary Supplement: Red PropolisPatients with chronic kidney disease will receive capsules containing 200mg of red propolis / day for two months. |
| Placebo Group | Placebo comparator | Other: Placebo ControlPatients with chronic kidney disease will receive capsules containing 200mg of placebo/ day for two months. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- patients with CKD stages 3-5 under conservative management
Key exclusion criteria (6 listed)
- pregnant,
- lactating,
- smoker
- patients using antibiotics and antioxidant supplements in the last three months
- patients with autoimmune and infectious diseases,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Red PropolisParticipants will receive 200mg of red propolis capsules per day for two months. | Dietary supplement | Red Propolis Group |
| Placebo ControlParticipants will receive 200mg of placebo capsules per day for two months. | Other | Placebo Group |
Primary outcome
Change in inflammatory biomarkers
Time frame: 8 weeks
Changes in the IL-6 and TNF-α
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
Related trials for Kidney Disease
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Red Propolis in people with Kidney Disease and Oxidative Stress, run by Universidade Federal Fluminense at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Denise Mafra, phd (21985683003, dmafra30@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in inflammatory biomarkers (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.